Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Neuropharmacology. 2013 Aug 16;0:10.1016/j.neuropharm.2013.07.032. doi: 10.1016/j.neuropharm.2013.07.032

Figure 5.

Figure 5

Reverse-dialysis of the nAChR antagonist mecamylamine impaired the performance of CHT+/− but not WT mice (see Results for the significant interaction between the effects of genotype, drug and signal duration on SAT scores). This interaction was mirrored in the analysis of hits, indicating that mecamylamine impaired hits to the longest signals in CHT+/− mice (b) but not WT animals (a). “Floor effects” may have limited the efficacy of mecamylamine to further lower hits to shorter signals. Corrected rejections and omissions were unaffected by mecamylamine.